Caixin
Caixin Global – Latest China News & Headlines

Home >

TRENDING
Nvidia Resumes H200 Chip Production for Chinese Market on Strong Demand
China Drone Sales Slump as Police Tighten Grip on Unauthorized Flights
China’s Zhipu AI Jumps in Hong Kong Debut
LATEST
Chinese AI Startup MiniMax Pops in Hong Kong Debut
China Drone Sales Slump as Police Tighten Grip on Unauthorized Flights
China to Review Meta’s Acquisition of AI Startup Manus
Chinese GPU-Maker Iluvatar CoreX Climbs in Hong Kong Debut With $5.3 Billion Valuation
China’s Zhipu AI Jumps in Hong Kong Debut
Nvidia Resumes H200 Chip Production for Chinese Market on Strong Demand
MiniMax’s Hong Kong IPO Oversubscribed 1,848 Times as AI Frenzy Builds
China’s Telecom Giants Back Smart-Glasses Maker RayNeo in $143 Million Funding Round
Robot-Maker Unitree’s IPO Expected by Mid-2026, Source Says
Xiaomi Targets 550,000 EV Sales in 2026
LandSpace Wins Nod for $1 Billion IPO Amid China’s Space Ambitions
Chinese AI Chipmaker Biren Skyrockets in Hong Kong Trading Debut
Baidu’s Chip Unit Kunlunxin Files for Hong Kong IPO to Tap AI Investment Boom
MiniMax Kicks Off $540 Million Hong Kong IPO Amid AI Gold Rush
Memory Chipmaker ChangXin Seeks $4.2 Billion in IPO Amid AI Boom
Moonshot AI Rules Out Quick IPO After Raising $500 Million
Enterprise AI Budgets to Swell Tenfold, Alibaba Cloud Exec Says
Smart-Home Startup OneRobotics Lands $206 Million in HK IPO, Bets Big on AI Bots
Chinese GPU-Maker Iluvatar CoreX Seeks $475 Million in Hong Kong Listing
Zhipu AI Seeks Up to $640 Million in Hong Kong IPO

By Han Wei / Dec 29, 2018 02:40 AM / Business & Tech

Photo: VCG

Photo: VCG

An initial investigation of herbal medicines and health foods producer Quanjian Group Co. Ltd. found that the company committed violations by exaggerating the benefits of its products, the state broadcaster China Central Television reported Friday.

A formal investigation has been initiated against Quanjian by the Tianjin city market regulator on allegations of violating market competition law, said the report.

Tianjin-based Quanjian has been under public scrutiny since Dingxiangyuan, an online health news portal, published an article Tuesday reporting that the company exaggerated the benefits of its products, which contributed to the 2015 death of a 4-year-old with cancer. Tianjin authorities sent inspectors to the company after the report went viral.

Quanjian also faces questions on whether it was involved in pyramid sales, which are banned in China. An official on the inspection team said the probe is still underway, according to the CCTV report.

Related: ‘Miracle’ Herbal Cures Accused of Contributing to Child's Death

Share this article
Open WeChat and scan the QR code